Omnipod 5 Simplify Life App User Guide

SmartAdjustTM Technology Overview
The Omnipod 5 system features SmartAdjustTM technology that automatically adjusts basal insulin to meet the user’s dynamic insulin needs. It adapts to daily changes and long-term developments like weight changes, growth, and aging.

Time in Range Improvement
Users switching from multiple daily injections (MDI) therapy experienced significant improvements in time in range and time below range, as supported by clinical data.

Proactive Correction & Protection
The SmartAdjust technology proactively corrects and protects against high glucose values by delivering microboluses and adjusting insulin delivery to prevent hypoglycemia.

Strong Settings for Strong Results
It is essential to set up the system correctly to achieve optimal results. Ensure initial basal rates, target glucose settings, and SmartBolus Calculator settings are accurately configured.

Omnipod® 5 and SmartAdjust™ technology

Adjusts basal insulin so you don’t have to1

HELPS TO
Correct and protect2,3

THERE ARE LOTS OF PUMPS. THERE’S ONLY ONE OMNIPOD® 5.

MORE TIME TO FOCUS ON

YOUR PATIENTS

SmartAdjust™ technology adjusts basal insulin automatically
No need to fine-tune basal settings. It adapts to your patient’s dynamic insulin needs in daily life and can also cover long-term developments like changes in weight, growth, and aging.1

In the real world

Adults switching from multiple daily injections (MDI) therapy showed

at an average target of 110 mg/dL.*

*Forlenza G, et al. Diabetes Technol Ther (2024). 5,091 adult Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL who utilized MDI as prior therapy had a time in range of 71.3% and time below range of 0.90%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.

HELPS TO PROACTIVELY

CORRECT & PROTECT

SmartAdjust technology delivers up to 38% of TDI in response to missed meal boluses4

When SmartAdjust predicts high glucose values, it will deliver a microbolus up to 400% of the patient’s adaptive basal rate, every 5 minutes. Additionally, it will proactively decrease or pause insulin delivery to help protect against hypoglycemia2,3

Example user with Total Daily Insulin (TDI) of 48
SmartAdjust technology is driven by total daily insulin. Optimal results can be achieved with the right balance between automated insulin delivery and bolusing from the user.

System determines
the adaptive basal rate based on an approximately 50/50 basal-bolus split: 24 units of adaptive basal rate
Max correction: 4 units per hour

Around 9 am, hyperglycemia is predicted. As a response, the system increases microboluses every 5 minutes until the user’s glucose levels return into range.
Between 9 am and 12:30 pm, approximately 10.35 units were delivered. After the initial correction, insulin delivery is proactively decreased to help protect against hypoglycemia.2,3

STRONG SETTINGS FOR

STRONG RESULTS

Set your patients up for success with the following recommendations
Rethink settings! Transferring settings unchanged from other AID systems, Pumps or MDI therapy may not lead to the optimal results.

Initial basal rates
SmartAdjust uses the programmed Basal Rate to calculate the initial total daily insulin amount. Be sure initial basal settings accurately represent your patients needs:

For patients transitioning from MDI, ensure that programmed basal rate accounts for 40- 50% of total daily insulin (basal+bolus)
For patients transitioning from other pumps or AID systems, be sure to consider historical total daily insulin

After initiation, the programmed basal rates do not affect the Adaptive Basal Rate in Automated Mode.

Target Glucose settings
Pay close attention to Target Glucose, it is the only setting that directly impacts the aggressiveness of automated insulin delivery.

110 mg/dl Target Glucose generally results in increased time in range
Consider higher Target Glucose settings during consistent times of greater risk for hypoglycemia

SmartBolus Calculator settings
With automated insulin delivery, expect a redistribution of basal to bolus insulin. To configure the SmartBolus Calculator for increased bolus insulin distribution, consider the following steps:

Strengthen Insulin to Carbohydrate Ratios (up to 10-25% more*) and Correction Factors
Remember that you might want to adjust the “Correct Above” setting when changing to lower Target Glucose
Toggle OFF Reverse Correction, to calculate more bolus insulin when glucose is in target range
Lower hours of Duration of Insulin Action to subtract less insulin from user-initiated boluses

*Source: Berget et al. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People with Diabetes. Clin Diabetes. 2022;40(2):168-184. https://doi.org/10.2337/cd21-0083

OMNIPOD® 5

SIMPLIFY LIFE®

LEARN MORE
about the power of SmartAdjust™ technology

Insulet Corporation • 100 Nagog Park, Acton, MA 01720 • 800-591-3455 • omnipod.com/hcp

In Automated Mode, SmartAdjust technology uses your total daily insulin (TDI) to set a new Adaptive Basal Rate for you. Omnipod 5 User Manual. P. 291

Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 – 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM.
Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 – 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 – 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM.
Ekhalaspour L, et al. Poster presented at: ATTD; March 6-9, 2024; Florence, Italy. Real-world data from 500 adults with type 1 diabetes using Omnipod 5. Data analyzed to find the percentage of TDI administered in the 4-hour period following a missed meal bolus. Mean automated insulin delivery (% of total daily dose) of 15.6% delivered in the 4-hour period following an analysis of 1,370 missed meal boluses. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available, and average Target Glucose of 110 mg/dL. Bolusing with the Omnipod 5 System is recommended for meals.

© 2024 Insulet Corporation. Omnipod and the Omnipod 5 logo are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. INS-OHS-07-2024-00123 v1.0Z

FAQ

Q: How does the SmartAdjust technology work?
A: SmartAdjust technology automatically adjusts basal insulin based on the user’s insulin needs, adapting to daily changes and long-term developments.

Q: What improvements can users expect with the Omnipod 5 system?
A: Users can expect improved time in range, reduced time below range, and proactive correction and protection against high and low glucose values.

Q: How should users set up the system for optimal results?
A: Users should ensure initial basal rates, target glucose settings, and SmartBolus Calculator settings are accurately configured to achieve strong results.

Documents / Resources

Omnipod 5 Simplify Life App [pdf] User Guide
5 Simplify Life App, Simplify Life App, Life App

References

User Manual

Omnipod 5 Simplify Life App

Product Information

Product Usage Instructions